Clearbridge Investments LLC reduced its position in shares of AstraZeneca plc (NYSE:AZN) by 6.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 309,859 shares of the company’s stock after selling 21,184 shares during the period. Clearbridge Investments LLC’s holdings in AstraZeneca were worth $10,752,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently added to or reduced their stakes in AZN. American International Group Inc. acquired a new stake in AstraZeneca during the 4th quarter worth approximately $1,976,000. Russell Investments Group Ltd. raised its holdings in AstraZeneca by 198.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,856,140 shares of the company’s stock valued at $62,883,000 after acquiring an additional 1,235,239 shares in the last quarter. Hardman Johnston Global Advisors LLC acquired a new position in AstraZeneca in the 4th quarter valued at $35,125,000. Arrowstreet Capital Limited Partnership acquired a new position in AstraZeneca in the 4th quarter valued at $25,455,000. Finally, Janus Henderson Group PLC raised its holdings in AstraZeneca by 5,754.0% in the 3rd quarter. Janus Henderson Group PLC now owns 726,599 shares of the company’s stock valued at $24,617,000 after acquiring an additional 714,187 shares in the last quarter. 15.15% of the stock is owned by institutional investors and hedge funds.
AstraZeneca plc (AZN) opened at $34.59 on Friday. AstraZeneca plc has a 52 week low of $28.43 and a 52 week high of $36.70. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.93. The stock has a market capitalization of $85,662.54, a price-to-earnings ratio of 7.90, a PEG ratio of 2.02 and a beta of 0.71.
The firm also recently declared a semiannual dividend, which will be paid on Monday, March 19th. Stockholders of record on Friday, February 16th will be paid a $0.95 dividend. The ex-dividend date of this dividend is Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s payout ratio is 57.81%.
Several equities analysts have weighed in on the company. BMO Capital Markets reaffirmed a “buy” rating and issued a $38.00 price objective on shares of AstraZeneca in a report on Friday, January 26th. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Monday, January 22nd. ValuEngine raised AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Saturday, February 3rd. Leerink Swann reaffirmed a “market perform” rating and issued a $36.00 price objective (up from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Finally, Sanford C. Bernstein lifted their price objective on AstraZeneca from $40.00 to $42.00 and gave the company an “outperform” rating in a report on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have issued a buy rating to the stock. AstraZeneca has an average rating of “Hold” and a consensus target price of $36.26.
ILLEGAL ACTIVITY NOTICE: “Clearbridge Investments LLC Reduces Position in AstraZeneca plc (AZN)” was originally reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this story on another website, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this story can be read at https://stocknewstimes.com/2018/03/17/clearbridge-investments-llc-reduces-position-in-astrazeneca-plc-azn.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.